ArticleHereditas2025
Correlation of CRP/Albumin ratio and low serum albumin with the risk of major adverse cardiovascular events in elderly patients with chronic total occlusion.
Article in Hereditas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06952647 (Hematological and Metabolic Markers in Carpal Tunnel Syndrome), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Hematological and Metabolic Markers in Carpal Tunnel Syndrome
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveThe C-reactive protein (CRP)/albumin (ALB) ratio (CAR), a key marker of inflammation and nutrition is closely associated with the risk of cardiovascular events. CAR’s potential to predict major adverse cardiovascular events (MACE) in elderly individuals with chronic total occlusion (CTO) has not been evaluated. Therefore, the aim of this study was to elucidate the correlation between CAR and the risk of MACE in elderly patients with CTO.
methodsThis prospective cohort study consecutively included 134 patients with CTO. ALB and CRP concentrations were measured after patient admission, and CAR was calculated. Patients were followed up by telephone for a median period of 12 months and categorized into a MACE group (41 patients) and a no-MACE group (93 patients) according to the occurrence of MACE during the follow-up period. The relationship between CAR and the risk of MACE was analyzed by COX regression, and the performance of ALB, CRP, and CAR in predicting the risk of MACE was assessed using ROC curve. Kaplan-Meier survival curves were used to analyze patient survival, with subgroup analysis based on CAR.
resultsThe incidence of MACE in 134 CTO patients was 30.60%. ALB (HR, 0.693; 95% CI, 0.588–0.861; P = 0.001) and CAR (HR, 1.128; 95% CI, 1.050–1.212; P = 0.001) were shown to be independent predictors of MACE in patients with CTO. The AUC for CAR was 0.807, surpassing the AUCs of CRP at 0.766 and ALB at 0.700 individually. The ROC curve indicated that the optimal value to distinguish between MACE and no-MACE groups was 0.1210. Patients with CAR ≥ 0.1210 and ALB < 35.86 g/L had a significantly higher risk of MACE over 2 years (P < 0.001). Final subgroup analysis showed no significant interaction between CAR and each subgroup (interaction P: 0.056–0.859).
conclusionCAR independently predicts MACE in CTO patients and provides superior prognostic value compared to using CRP or ALB alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.